TG Therapeutics Inc (NASDAQ:TGTX) reached a new 52-week high on Monday . The company traded as high as $9.73 and last traded at $9.18, with a volume of 3180263 shares. The stock had previously closed at $7.12.
TGTX has been the topic of several research analyst reports. B. Riley started coverage on shares of TG Therapeutics in a report on Wednesday, November 27th. They issued a “buy” rating and a $12.00 price objective on the stock. ValuEngine lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of TG Therapeutics in a research report on Tuesday, November 12th. BidaskClub raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 7th. Finally, Zacks Investment Research lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $12.95.
The company has a fifty day moving average of $7.22 and a 200-day moving average of $6.94. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 2.77.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC increased its stake in TG Therapeutics by 6,258.4% during the 3rd quarter. Millennium Management LLC now owns 7,521,910 shares of the biopharmaceutical company’s stock worth $42,235,000 after buying an additional 7,403,611 shares during the period. BlackRock Inc. raised its holdings in TG Therapeutics by 19.5% in the second quarter. BlackRock Inc. now owns 5,304,463 shares of the biopharmaceutical company’s stock valued at $45,883,000 after acquiring an additional 866,572 shares in the last quarter. Vanguard Group Inc. lifted its stake in TG Therapeutics by 19.7% in the second quarter. Vanguard Group Inc. now owns 4,041,122 shares of the biopharmaceutical company’s stock worth $34,955,000 after acquiring an additional 665,380 shares during the last quarter. Sofinnova Investments Inc. lifted its stake in TG Therapeutics by 258.5% in the second quarter. Sofinnova Investments Inc. now owns 1,261,384 shares of the biopharmaceutical company’s stock worth $10,911,000 after acquiring an additional 909,573 shares during the last quarter. Finally, Camber Capital Management LP acquired a new position in TG Therapeutics during the 2nd quarter worth approximately $8,650,000. 48.64% of the stock is owned by institutional investors and hedge funds.
TG Therapeutics Company Profile (NASDAQ:TGTX)
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Featured Article: CD Ladder
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.